617718-45-3

Usage

Uses

Used in Medicinal Chemistry:
1-Benzhydryl-3-fluoroazetidine is used as a building block or intermediate in the synthesis of pharmaceutical compounds for [application reason]. Its unique structure and reactivity, due to the presence of the fluorine atom, may contribute to the development of new drugs with improved properties, such as enhanced bioavailability, selectivity, or potency.
Used in Organic Synthesis:
1-Benzhydryl-3-fluoroazetidine is used as a reagent or catalyst in various organic synthesis processes for [application reason]. Its complex structure and potential reactivity make it a valuable component in the creation of new organic molecules with specific properties and functions.
Used in Research and Development:
1-Benzhydryl-3-fluoroazetidine is used as a research compound in academic and industrial laboratories for [application reason]. Its unique structure and potential reactivity provide opportunities for studying new chemical reactions, mechanisms, and the development of novel synthetic strategies.
Used in Material Science:
1-Benzhydryl-3-fluoroazetidine is used as a component in the development of new materials with specific properties for [application reason]. Its incorporation into polymers, coatings, or other materials may lead to the creation of innovative products with improved performance, such as enhanced stability, durability, or functionality.

Upstream product

• 51411-28-0 N-(diphenylmethylene)-2-propen-1-amine 
• 40320-60-3 N-benzhydryl 3-azetidinone 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 

Downstream Products

• 869488-99-3 benzhydryl-3-fluoroazetidine hydrochloride 

Relevant academic research and scientific papers

Alcohol compound-based in-situ deoxygenation fluorination synthesis method and alcohol compound-based F radiolabeling method

The invention discloses an alcohol compound-based in-situ deoxidation fluorination synthesis method and an alcohol compound-based F radiolabeling method. Alkyl alcohols such as 4-phenyl-1-butanol,which are used as raw materials, react with trifluorome

9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUND

The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.

9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS

The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.

Synthesis of 3-fluoroazetidines

N-(Alkylidene or 1-arylmethylidene)-2-propenylamines were regiospecifically functionalized to novel N-(alkylidene or 1-arylmethylidene)-3-bromo-2- fluoropropylamines, which were proven to be excellent precursors for 3-fluoroazetidines.

Therapeutic compounds

The invention provides compounds of formula (I), prodrugs and stereoisomers thereof, and the pharmaceutically acceptable salts of the compounds, prodrugs, and stereoisomers, wherein R1, R2, R3, HET, n, Q, X, Y, and Z are as described herein; compositions thereof; and uses thereof in treating diabetic complications including diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, and the like.

FUSED PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to fused phenylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to phenylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.